TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Memphasys Ltd ( (AU:MEM) ) has provided an announcement.
Memphasys Limited is advancing the commercialisation of its Felix™ sperm-selection device through a direct sales strategy in the Middle East, focusing on converting clinical interest into purchasing behavior and recurring revenue. The strategy includes direct engagement with IVF clinics in Qatar and the UAE, aiming to prepare them for immediate purchasing upon anticipated CE Mark approval in early 2026. This initiative, highlighted by a keynote address at the Middle East Fertility Society Conference, is expected to significantly expand Memphasys’ market presence and revenue potential in the region.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited is a company operating in the medical technology industry, specializing in reproductive biotechnology. The company focuses on developing and commercializing advanced sperm separation devices, with a particular emphasis on the Felix™ sperm-selection device, aimed at improving fertility treatment outcomes.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.46M
For detailed information about MEM stock, go to TipRanks’ Stock Analysis page.